The Republican Unitary Enterprise “BelLekoCenter” under the Administration of the President of the Republic of Belarus has reached out to Indian pharmaceutical companies for 84 high-quality medicines.
According to a report by Pharmabiz, these medicines are prescribed to treat a wide variety of diseases. Some of the medicines include pertuzumab to treat breast cancer, tocilizumab to treat rheumatoid arthritis and juvenile idiopathic arthritis, adalimumab to treat various autoimmune conditions such as rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, Crohn disease, and ulcerative colitis, azacitidine used for the treatment of myelodysplastic syndrome, myeloid leukemia, and juvenile myelomonocytic leukemia.
Other products include nilotinib, abiraterone, sunitinib, baricitinib, palbociclib and eptacog alfa (coagulation factor VIIa activated), tacrolimus, bevacizumab, rituximab and trastuzumab.
Alexey Litskevich, the director of BelLekoCenter, expressed the enterprise’s interest in sourcing safe and effective medicines from India, as per Pharmabiz report. The request received by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), highlighted the specific requirements and highlighted the importance of quality in the procurement process.
Reportedly, this trade inquiry signals a potential opportunity for Indian pharmaceutical companies to expand their market reach into Belarus.
“Companies operating in Belarus or dealing with the mentioned products are encouraged to directly engage with Alexey Litskevich for further discussions and potential collaboration. This initiative not only underscores the growing global demand for Indian pharmaceuticals but also highlights the efforts of organizations like Pharmexcil in facilitating international trade partnerships,” said Uday Bhaskar, the director general (DG) of Pharmexcil.
As discussions progress, the outcome of this trade inquiry could potentially strengthen bilateral ties between India and Belarus in the healthcare sector, ultimately benefiting patients in both countries, it stated.